

## Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011 Provincial Funding Summary

The interim Joint Oncology Drug Review (iJODR) was the precursor oncology drug review process prior to pCODR, which provided evidence-based recommendation for cancer treatments from early 2007 until the transition to the pan-Canadian Oncology Drug Review (pCODR) in June 2011.

This information should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, or as a substitute for professional medical advice. This information is intended for informational and educational purposes only.

pCODR, a program of CADTH, does not endorse any information, drugs, therapies, treatments, products, processes, or services. All information contained in this document is provided on an as-is basis without any representations, warranties or endorsements whatsoever and pCODR disclaims any intention or obligation to update or revise such information, except as required by law. A drug that is funded does not necessarily mean it is funded for all patients for the listed indication and there are specific funding criteria that the patient must meet. Please contact the specific provincial drug programs and cancer agencies for the funding criteria and program eligibility. Please contact [info@pcodr.ca](mailto:info@pcodr.ca) with any inquiries about the information contained in this document.

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Abiraterone	Zytiga	Metastatic prostate cancer, castrate resistant, prior docetaxel	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Not Funded
Alemtuzumab	Mabcampath	B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy	Funded	Not Funded	Not Funded	Funded	Not Funded	Funded			Not Funded
Alemtuzumab	Mabcampath	Previously untreated progressive B-cell chronic lymphocytic leukemia (B-CLL)	Funded	Not Funded	Not Funded	Not funded	Not funded	Funded			Not Funded
Azacitidine	Vidaza	Non-transplant myelodysplastic syndrome	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Bevacizumab	Avastin	Unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen	Not funded	Not Funded	Not Funded	case-by-case	Not Funded	Not Funded			Not Funded
Bevacizumab	Avastin	Glioblastoma after relapse or disease progression, following prior therapy	Funded	Not Funded	Funded	Funded	Not Funded	Not Funded			Not Funded
Bortezomib	Velcade	Mantle cell lymphoma who have relapsed or were refractory to at least one prior therapy	Not funded	Funded	Not Funded	case-by-case	Not Funded	Not Funded			Not Funded
Bortezomib	Velcade	Previously untreated multiple myeloma patients who are unsuitable for stem cell transplantation, as part of combination therapy	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Cabazitaxel	Jevtana	In combination with prednisone or prednisolone is indicated for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded

Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Capecitabine	Xeloda	For the adjuvant treatment of patients with stage III (Dukes' Stage C) colon cancer	Funded	Funded	Funded	Funded	Funded	Funded	Funded		Funded
Capecitabine	Xeloda	In combination with oxaliplatin for the treatment of metastatic colorectal cancer following failure of irinotecan-containing combination chemotherapy	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Cetuximab	Erbitux	EGFR-expressing metastatic colorectal carcinoma (CRC) in patients who are refractory to other irinotecan-based chemotherapy regimens, single agent treatment	Funded	Not Funded	Funded	Funded	Funded	Funded			Not Funded
Cetuximab	Erbitux	In combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Dasatinib	Sprycel	Adults with chronic, accelerated, or blast phase CML with resistance or intolerance to prior therapy including imatinib mesylate	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Dasatinib	Sprycel	Adults with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy	Funded	Not Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Degarelix	Firmagon	Advanced prostate cancer, advanced hormone-dependent prostate cancer in whom androgen deprivation is warranted	Funded	Not Funded	Funded	Funded	Funded	Funded	Funded	Not funded	Funded
Docetaxel + Cyclophosphamide		Early operable breast cancer	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Erlotinib	Tarceva	As monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and whose EGFR expression status is positive or unknown.	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Erlotinib	Tarceva	As monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease after 4 cycles of standard platinum-based first-line chemotherapy	Funded	Not Funded	Not Funded	case-by-case	Not Funded	Not Funded	Not funded	Not funded	Not Funded

Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Everolimus	Afinitor	Metastatic renal cell carcinoma (RCC) of clear cell morphology, after failure of initial treatment with either of the VEGF-receptor TKIs sunitinib or sorafenib	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Not Funded
Fludarabine	Fludara	Previously untreated chronic lymphocytic leukemia	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Fulvestrant	Faslodex	Hormonal treatment of locally advanced or metastatic breast cancer in postmenopausal women, regardless of age, who have disease progression following prior anti-estrogen therapy.	Not funded	Not Funded	Not Funded	Not funded	Not Funded	Not Funded	Not Funded	Not funded	Not Funded
Gefitinib	Iressa	For the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK	Funded	Funded	Funded	Funded	Funded	Not Funded	Not funded	Not funded	Not Funded
Gemcitabine	Gemzar	Metastatic breast cancer	Funded	Funded	Funded	Funded	Not Funded	Not Funded			Funded
Histrelin	Vantas	Implant for metastatic prostate cancer; palliative treatment of hormone-dependent advanced prostate cancer (Stage M1 [TNM] or Stage D2 [AUA])	Not funded	Not Funded	Not Funded	Not funded	Not Funded	Not Funded	Not Funded	Not funded	Not Funded
Imatinib	Gleevec	As a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Funded	Funded	Funded	Funded	Funded	Case by case	Funded	Funded	Funded
Imatinib	Gleevec	For the adjuvant treatment of adult patients who are at intermediate to high risk of relapse following complete resection of Kit (CD117) positive GIST	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Not funded	Not Funded
Lapatinib	Tykerb	In combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress ErbB2 [Human Epidermal Receptor Type 2 (HER2)]. Patients should have progressed on taxanes, anthracycline and trastuzumab before starting therapy HER2+	Funded	Funded	Funded	Not funded	Funded	Funded	Funded	Not funded	Not Funded

Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Lenalidomide	Revlimid	Patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Lenalidomide	Revlimid	In combination with dexamethasone, for the treatment of multiple myeloma patients who have received at least one prior therapy	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Liposome-Encapsulated Doxorubicin	Myocet	Metastatic breast cancer	Not funded	Not Funded	Not Funded	case-by-case	Not Funded	Not Funded			Not Funded
Methyl Aminolevulinate (Aminolevulinic Acid)	Metvix	Superficial basal cell cancer	Funded	Not Funded	Not Funded	Not funded	Not Funded	Not Funded		Not funded	Not Funded
Nab-Paclitaxel	Abraxane	Metastatic breast cancer	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Nilotinib	Tasigna	Accelerated phase (AP) Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib	Funded	Funded	Funded	Funded	Funded		Funded	Funded	Funded
Nilotinib	Tasigna	Chronic phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at least one prior therapy including imatinib	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Nilotinib	Tasigna	For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase	Not funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Not Funded
Oxaliplatin	Eloxatin	In combination with 5-fluorouracil (5-FU) and leucovorin (LV) as treatment for patients with metastatic colorectal cancer	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Oxaliplatin	Eloxatin	In combination with infusional 5-fluorouracil and leucovorin as adjuvant treatment of patients with stage III (Duke's C) colon cancer after complete resection of primary tumor	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Oxaliplatin	Eloxatin	In combination with bevacizumab for metastatic colorectal cancer, first line	Funded	Not Funded	Funded	Funded	Funded	Funded			Funded
Oxaliplatin	Eloxatin	For metastatic colorectal cancer, second line, refractory or intolerant to irinotecan-based therapy	Funded	Funded	Funded	Funded	Funded	Funded			Funded

Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Panitumumab	Vectibix	As monotherapy for the treatment of patients with EGFR expressing metastatic colorectal carcinoma (mCRC) with non-mutated (wild-type) KRAS after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Pegylated Liposomal Doxorubicin	Caelyx	Metastatic breast cancer	Not funded	Not Funded	Not Funded	case-by-case	Not Funded	Not Funded			Funded
Pemetrexed	Alimta	As monotherapy as a treatment option for patients with locally advanced or metastatic non-small cell lung cancer after prior chemotherapy	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Pemetrexed	Alimta	In combination with cisplatin therapy is indicated for the initial treatment of good performance status patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Pemetrexed	Alimta	Maintenance treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer, in a good performance status patients without disease progression immediately following four cycles of first-line platinum doublet chemotherapy, excluding pemetrexed	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Rituximab	Rituxan	Previously untreated B-cell chronic lymphocytic leukemia (B-CLL), stage B or C, in combination with fludarabine and cyclophosphamide	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Rituximab	Rituxan	For refractory chronic lymphocytic leukemia (CLL)	Not funded	Not Funded	Not Funded	Funded	Funded	Funded			Funded
Sorafenib	Nexavar	Locally advanced/metastatic renal cell (clear cell) carcinoma (RCC) in patients who failed prior cytokine therapy or are considered unsuitable for such therapy	Funded	Funded	Not Funded	Funded	Funded	Funded	Funded	Funded	Funded
Sorafenib	Nexavar	Treatment of patients with unresectable hepatocellular carcinoma (HCC)	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded

Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011

Generic Name	Brand Name	Indication	BC	AB	SK	MB	ON	NS	NB	NL	PEI
Sunitinib	Sutent	Metastatic renal cell carcinoma of clear cell histology after failure of cytokine-based therapy or in patients who are considered likely to be intolerant of such therapy	Funded	Funded	Funded	Funded	Funded	Funded	Funded		Funded
Sunitinib	Sutent	Metastatic renal cell carcinoma (mRCC) of clear cell histology.	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Temsirolimus	Torisel	Metastatic renal cell cancer	Funded	Funded	Funded	Funded	Funded	Funded			Not Funded
Thalidomide	Thalomid	For patients with previously untreated multiple myeloma, in combination with melphalan and prednisone	Funded	Not Funded	Not Funded	Not Funded	Funded	Not funded	Not funded	Not funded	Not Funded
Thyrotropin	Thyrogen	Thyroid cancer	Funded	Not Funded	Funded	Funded	Funded	Funded	Funded	Funded	Funded
Topotecan	Hycamtin	Small cell lung cancer	Funded	Funded	Funded	Funded	Not Funded	Funded			Funded
Trastuzumab	Herceptin	Early stage breast cancer whose tumours overexpress her2 following surgery and after chemotherapy	Funded	Funded	Funded	Funded	Funded	Funded			Funded
Trastuzumab	Herceptin	In combination with capecitabine or intravenous 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.	Funded	Funded	Funded	Funded	Funded	Not Funded			Not Funded